How a Swiss Biotech and a Kyoto Pharma Company Joined Forces on an Ultra-Rare Childhood Inflammatory DiseaseBusiness PenJuly 30, 2026 July 30, 2026 [stock_market_widget type=”card” template=”basic2″ assets=”4516.T” realtime=”true” api=”yahoo-finance”] For a small group of children born with two rare genetic disorders, there has never been a medicine designed...
